D. Church

486 total citations
11 papers, 386 citations indexed

About

D. Church is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, D. Church has authored 11 papers receiving a total of 386 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Pharmacology. Recurrent topics in D. Church's work include Pneumonia and Respiratory Infections (6 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Antibiotic Resistance in Bacteria (3 papers). D. Church is often cited by papers focused on Pneumonia and Respiratory Infections (6 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Antibiotic Resistance in Bacteria (3 papers). D. Church collaborates with scholars based in United States, Germany and Canada. D. Church's co-authors include Daniel Haverstock, C. Andrew DeAbate, Sanford Chodosh, Allen Heyd, John Harley Warner, Matthew E. Levison, Mark J. Ingerman, Elías Abrutyn, B E Murray and Audrey Wanger and has published in prestigious journals such as CHEST Journal, Antimicrobial Agents and Chemotherapy and Respiratory Medicine.

In The Last Decade

D. Church

9 papers receiving 359 citations

Peers

Countries citing papers authored by D. Church

Since Specialization

Citations

This map shows the geographic impact of D. Church's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Church with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Church more than expected).

Fields of papers citing papers by D. Church

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Church. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Church. The network helps show where D. Church may publish in the future.

Co-authorship network of co-authors of D. Church

This figure shows the co-authorship network connecting the top 25 collaborators of D. Church. A scholar is included among the top collaborators of D. Church based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Church. D. Church is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	FEASIBILITY, SAFETY, AND EFFICACY OF NEBULIZED LONG-ACTING BRONCHODILATORS VS NEBULIZED SHORT-ACTING BRONCHODILATORS IN HOSPITALIZED PATIENTS WITH EXACERBATIONS OF COPD 2023 ·CHEST Journal ·Rajiv Dhand, (unknown), (unknown), Paul Terry, (unknown), (unknown), D. Church, (unknown), (unknown), (unknown), (unknown), R. Eric Heidel, (unknown), (unknown), (unknown), (unknown)	0
2	The Microbiome in Nebulizers Used with Mouthpieces or Facemasks by Hospitalized Non-Cystic Fibrosis Patients 2020 ·(unknown), Qiang He, (unknown), (unknown), (unknown), (unknown), D. Church, (unknown), Rajiv Dhand	0
3	Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens 2004 ·European Journal of Clinical Microbiology & Infectious Diseases ·Gert Hoeffken, David A. Talan, (unknown), (unknown), Shurjeel H Choudhri, Daniel Haverstock, (unknown), D. Church	15
4	Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia 2003 ·Respiratory Medicine ·H. Lode, Charles M. Grossman, Shurjeel Choudhri, Daniel Haverstock, (unknown), (unknown), D. Church	21
5	PIN17 PRELIMINARY RESULTS OF A U.S.-BASED STUDY TO VALIDATE THE ACUTE BRONCHITIS SYMPTOM SEVERITY SCALE 2002 ·Value in Health ·NK Leidy, (unknown), (unknown), Kathleen Gondek, (unknown), (unknown), Shurjeel Choudhri, D. Church	1
6	MOXIFLOXACIN VERSUS CEPHALEXIN IN THE TREATMENT OF UNCOMPLICATED SKIN INFECTIONS 2000 ·International Journal of Clinical Practice ·(unknown), (unknown), (unknown), (unknown), Philip Werschler, Allen Heyd, Daniel Haverstock, D. Church	38
7	Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia 2000 ·Respiratory Medicine ·Twisha S Patel, Jeffrey Pearl, Julian Williams, Daniel Haverstock, D. Church	41
8	The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis 2000 ·Respiratory Medicine ·C. Andrew DeAbate, (unknown), John Harley Warner, Allen Heyd, D. Church	75
9	Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis 2000 ·Respiratory Medicine ·Sanford Chodosh, C. Andrew DeAbate, Daniel Haverstock, (unknown), D. Church	105
10	Does appropriate antibiotic treatment influence outcome in community-acquired pneumonia (CAP)? 2000 ·Respiratory Medicine ·Michael S. Niederman, D. Church, (unknown), (unknown)	3
11	Comparison of two beta-lactamase-producing strains of Streptococcus faecalis 1986 ·Antimicrobial Agents and Chemotherapy ·B E Murray, D. Church, Audrey Wanger, (unknown), Matthew E. Levison, Mark J. Ingerman, Elías Abrutyn, (unknown)	87

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact